Bothrops diporus, previously considered a subspecies of the B. neuwiedi complex, is a medically relevant viperid in Northeastern Argentina. The venom of this species causes local tissue damage characterized by myonecrosis, hemorrhage, blistering, and edema. In the present study, two basic phospholipases A (PLA-I and PLA-II) were isolated from this venom, and their pathological effects upon murine skeletal muscle and myogenic cells in culture were analyzed. Partial amino acid sequencing showed that PLA-I and PLA-II are Asp49 and Lys49 PLAs, respectively. In agreement with this, PLA-I showed PLA activity, whereas PLA-II did not. Functional assays revealed differences in their myotoxicity, cytotoxicity, and anti-adhesion activity, and in the ability to inhibit cell migration, all of which were greater for the Lys49 variant. Native electrophoresis showed that PLA-I was less basic than PLA-II. The two proteins act synergistically to affect the integrity of CC myogenic cells, providing a further example of the concerted action of coexisting snake venom components. PLA-I and PLA-II, together with additional basic PLAs revealed by RP-HPLC, probably play an important role in myonecrosis after envenomation by B. diporus.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.toxicon.2019.07.004 | DOI Listing |
HIV AIDS (Auckl)
August 2021
HIVCENTER, Medical HIV Treatment and Research Unit, Johann Wolfgang Goethe University Frankfurt, Frankfurt am Main, Germany.
Background: In the past, protease inhibitors (PIs) and the reverse transcriptase inhibitor abacavir were identified increasing the risk for thromboembolic complications and cardiovascular events (CVE) of HIV infected patients taking a combination antiretroviral therapy (cART). Results of the previous HIV-PLA I-study lead to the assumption that platelet activation could play a substantial role in increasing CVE risks.
Methods: The open label, monocentric HIV-PLA II-study investigated HIV-1-infected, therapy-naïve adults (n=45) starting with cART, consisting either of boosted PI (atazanavir, n= 6, darunavir, n=11), NNRTI (efavirenz, n=14) or integrase inhibitor (raltegravir, n=14), each plus tenofovir/emtricitabine co-medication.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!